death and events prevention

Description Results NMA

Total mortality 0.70 [0.48; 1.01]

Cardiovascular death 0.70 [0.47; 1.02]

Non-fatal MI 0.89 [0.54; 1.46]

Total mortality 0.74 [0.52; 1.05]

Total mortality 0.83 [0.65; 1.05]

Cardiovascular death 0.50 [0.27; 0.92]

Fatal MI 0.38 [0.17; 0.85]

Non-fatal MI 0.47 [0.29; 0.75]

Total mortality 0.68 [0.44; 1.05]

Non-fatal MI 0.78 [0.63; 0.96]

Total mortality 1.11 [0.94; 1.32]

Total mortality 0.82 [0.51; 1.34]

Fatal MI 0.49 [0.17; 1.41]

Non-fatal MI 0.71 [0.33; 1.53]

Total mortality 0.82 [0.59; 1.13]

Cardiovascular death 0.82 [0.58; 1.17]

Non-fatal MI 0.70 [0.48; 1.03]

Non-fatal MI 0.27 [0.10; 0.72]

Total mortality 1.18 [0.45; 3.12]

Cardiovascular death 1.10 [0.34; 3.57]

Non fatal MI 0.67 [0.45; 0.98]

vascular event 0.71 [0.57; 0.89]

vascular death 0.76 [0.54; 1.07]

Non fatal stroke 0.79 [0.45; 1.39]

non vascular death 1.66 [0.79; 3.51]

Aspirin (324 mg) 3x/d (n=758)

vs.

Placebo (n=771)

Double blind

Parallel groups

Sample size: 758/771

Primary endpoint: No primary outcome clearly defined

FU duration: 1.83 y

Aspirin (300 mg) 1x/d (n=615)

vs.

Placebo (n=624)

Double blind

Parallel groups

Sample size: 615/624

Primary endpoint: Total mortality

FU duration: 2 years

Aspirin (300 mg) 3x/d for one year (n=832)

vs.

Placebo (n=850)

Double blind

Parallel groups

Sample size: 832/850

Primary endpoint: Total mortality

FU duration: 1 y

Aspirin (1.5 g daily) on an average period of 22 months (n=672)

vs.

Placebo (n=668)

Double blind

Parallel groups

Sample size: 672/668

Primary endpoint: Death or reinfraction

FU duration: 1.75 y (mean)

Aspirin (500 mg) 2x/d for at least 3 years (n=2267)

vs.

Placebo (n=2257)

Double blind

Parallel groups

Sample size: 2267/2257

Primary endpoint: Total mortality

FU duration: > 3 y

Aspirin (500 mg) 3x/d for 2 years (n=317)

vs.

Placebo (n=309)

Double blind

Parallel groups

Sample size: 317/309

Primary endpoint: No primary outcome clearly defined

FU duration: 2 y

part of a 3-group trial

Aspirin (324 mg) 3x/d (n=810)

vs.

Placebo (n=406)

Double blind

Parallel groups

Sample size: 810/406

Primary endpoint: No primary outcome clearly defined

FU duration: 41 mo

part of 3-group trial

Aspirin (81 mg) 1x/d (n=250)

vs.

No antiplatelets (n=230)

Open

Parallel groups

Sample size: 250/230

Primary endpoint: No primary outcome clearly defined

FU duration: 1.3 y (mean)

part of a 3-group trial

aspirin 75 mg daily (n=1009)

vs.

placebo (n=1026)

double blind

Parallel groups

Sample size: 1009/1026

Primary endpoint: myocardial infarction and sudden death

FU duration: 50 months

vascular event 0.90 [0.63; 1.29]

Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years (n=9599)

vs.

Aspirin (325 mg) 1x/d (n=9586)

Double blind

Parallel groups

Sample size: 9599/9586

Primary endpoint: ischaemic stroke, myocardial infarction, vascular death

FU duration: 1.91 y

clopidogrel 75 mg once daily for two years (n=498)

vs.

Aspirin 160 mg once daily for two years (n=503)

platelet function was also assessed at randomization with the PFA100 method and platelet aggregometry

open

Parallel groups

Sample size: 498/503

Primary endpoint: all-cause death, nonfatal MI, ischemic stroke, and unstable angina

FU duration:

Stroke 0.63 [0.25; 1.58]

Stroke 0.61 [0.35; 1.05]

vascular death ∞ [NaN; ∞]

Non fatal stroke ∞ [NaN; ∞]

Non fatal MI 0.75 [0.18; 3.07]

non vascular death NaN [NaN; NaN]

vascular event 1.25 [0.37; 4.21]

vascular death ∞ [NaN; ∞]

Non fatal stroke NaN [NaN; NaN]

Non fatal MI NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

vascular event ∞ [NaN; ∞]

vascular death NaN [NaN; NaN]

Non fatal stroke NaN [NaN; NaN]

Non fatal MI NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

vascular event NaN [NaN; NaN]

Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810)

vs.

Placebo (n=406)

Double blind

Parallel groups

Sample size: 810/406

Primary endpoint: No primary outcome clearly defined

FU duration: 41 months (mean)

part of 3-group trial

Aspirin (330 mg) + dipyridamole (75 mg) 3x/d (n=1563)

vs.

Placebo (n=1565)

Double blind

Parallel groups

Sample size: 1563/1565

Primary endpoint: No primary outcome clearly defined

FU duration: 23.4 months

dipyridamole 150mg daily (n=30)

vs.

placebo (n=30)

double-blind

parallel groups

Sample size: 30/30

Primary endpoint: not defined

FU duration: 6 months

dipyridamole 225mg daily (n=14)

vs.

placebo (n=13)

double-blind

parallel groups

Sample size: 14/13

Primary endpoint: not defined

FU duration: 5 months

dipyridamole 150mg daily (n=28)

vs.

placebo (n=28)

double blind

parallel groups

Sample size: 28/28

Primary endpoint: not defined

FU duration: 7 months

Dipyridamole 200mg daily (n=26)

vs.

placebo (n=22)

double blind

parallel groups

Sample size: 26/22

Primary endpoint: not defined

FU duration: 2-7 months

Dipyridamole 37.5mg (n=14)

vs.

placebo (n=14)

double-blind

cross-over

Sample size: 14/14

Primary endpoint: not defined

FU duration: 0.5 months

dipyridamole 37.5 mg and 100mg daily (n=13)

vs.

placebo (n=13)

double-blind

parallel groups

Sample size: 13/13

Primary endpoint: not defined

FU duration: 0.5 months

dipyridamole 100mg daily (n=19)

vs.

placebo (n=19)

double blind

parallel groups

Sample size: 19/19

Primary endpoint: not defined

FU duration: >3 months

Dipyridamole 100mg daily (n=17)

vs.

placebo (n=17)

double-blind

parallel groups

Sample size: 17/17

Primary endpoint: not defined

FU duration: 0.5 months

dipyridamole 150mg daily (n=20)

vs.

placebo (n=16)

double-blind

parallel groups

Sample size: 20/16

Primary endpoint: not defined

FU duration: 1.5 months

Dipyridamole 200mg daily (n=24)

vs.

placebo (n=24)

double-blind

parallel groups

Sample size: 24/24

Primary endpoint: not defined

FU duration: 1 months

Death or nonfatal MI 1.05 [0.84; 1.30]

Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810)

vs.

Aspirin (324 mg) 3x/d (n=810)

Double blind

Parallel groups

Sample size: 810/810

Primary endpoint: No primary outcome clearly defined

FU duration: 41 months

part of 3-group trial

vascular death NaN [NaN; NaN]

Non fatal stroke NaN [NaN; NaN]

Non fatal MI NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

vascular event NaN [NaN; NaN]

ticlopidine 500 mg daily (n=21)

vs.

placebo (n=17)

double blind

parallel groups

Sample size: 21/17

Primary endpoint: not defined

FU duration: 2m